Mean (95% CI) changes in PD15 FEV1 values in doubling doses (DD) compared with baseline in fluticasone propionate (FP) and placebo groups and mean (95% CI) differences between groups
| Time from treatment onset | Fluticasone (n=13) | Placebo (n=13) | Difference (FP v placebo) |
|---|---|---|---|
| Post-treatment values are compared with those at baseline and at 6 weeks (last dose). n =11 in the FP group and n =12 in the placebo group in the post-treatment period at 48 hours, 1 week and 2 weeks. | |||
| Treatment v baseline | |||
| 6 hours | 0.58 (−0.07 to 1.22) | 0.63 (−0.17 to 1.43) | −0.06 (−1.03 to 0.92) |
| 12 hours | 1.26 (0.70 to 1.82) | 0.43 (−0.26 to 1.12) | 0.83 (−0.01 to 1.67) |
| 24 hours | 1.75 (1.08 to 2.43) | 1.03 (0.47 to 1.60) | 0.72 (−0.12 to 1.56) |
| 72 hours | 1.98 (1.33 to 2.63) | 0.79 (−0.11 to 1.70) | 1.19 (0.13 to 2.25) |
| 2 weeks | 1.92 (1.07 to 2.77) | 0.59 (−0.16 to 1.34) | 1.33 (0.26 to 2.40) |
| 4 weeks | 1.85 (0.88 to 2.82) | 0.58 (−0.15 to 1.31) | 1.27 (0.12 to 2.42) |
| 6 weeks | 2.07 (1.30 to 2.83) | 0.09 (−0.64 to 0.81) | 1.98 (0.98 to 2.98) |
| Post-treatment v baseline | |||
| 48 hours | 1.47 (0.32 to 2.61) | 0.66 (−0.12 to 1.45) | 0.81 (−0.48 to 2.09) |
| 1 week | 1.15 (0.01 to 2.29) | 0.11 (−0.74 to 0.96) | 1.04 (−0.29 to 2.3) |
| 2 weeks | 0.85 (−0.57 to 2.27) | 0.26 (−0.37 to 0.89) | 0.59 (−0.82 to 2.00) |
| Post-treatment v 6 weeks | |||
| 48 hours | −0.40 (−1.00 to 0.20) | 0.43 (−0.04 to 0.90) | (−0.83 (−1.54 to −0.12) |
| 1 week | −0.72 (−1.34 to −0.09) | −0.12 (−0.72 to 0.48) | −0.60 (−1.41 to 0.22) |
| 2 weeks | -1.02 (−2.19 to 0.16) | 0.03 (−0.58 to 0.63) | −1.04 (−2.25 to 0.17) |